Medical College of Wisconsin
CTSIResearch InformaticsREDCap

Associations of Patient Age, Tumor Nephrectomy Weight, and Tumor Diameter with Event-Free and Overall Survival in Stage I or II Favorable Histology Wilms Tumor: A Pooled Analysis of Children's Oncology Group Studies AREN0532 and AREN03B2. Ann Surg 2025 Apr 11

Date

04/11/2025

Pubmed ID

40211953

Pubmed Central ID

PMC12353671

DOI

10.1097/SLA.0000000000006726

Scopus ID

2-s2.0-105002399355 (requires institutional sign-in at Scopus site)   2 Citations

Abstract

OBJECTIVE: To evaluate age, TNW, or tumor diameter (TD) as continuous prognostic variables for outcomes in early stage FHWT after accounting for biology and treatment.

SUMMARY OF BACKGROUND DATA: Patient age (< 2 vs. ≥ 2 years) and tumor nephrectomy weight (TNW; < 550g vs. ≥ 550 grams) have been used to risk stratify children with stage I favorable histology Wilms tumor (FHWT) on Children's Oncology Group (COG) studies and select patients for omission of chemotherapy.

METHODS: Included patients had stage I or II FHWT per central review and were treated with nephrectomy only, EE4A, or DD4A on COG trials. Restricted cubic splines models were used to estimate the stage-specific effects of age, TNW, and TD on event-free survival (EFS) and overall survival (OS), accounting for treatment and biology.

RESULTS: In pooled analyses of 775 stage I and 936 stage II patients, age was not significantly associated with EFS or OS for stage I or II patients after accounting for adverse biology that is more prevalent with older age. Greater TNW and larger TD were associated with increased risk of relapse in stage I and increased risk of death in stage II, but not when restricted to patients less than 4 years old.

CONCLUSIONS: Age, TNW, and TD are each prognostic for EFS or OS in some cohorts of patients with stage I or II FHWT. However, after accounting for adverse biology that becomes more prevalent at older ages, these factors are no longer independently prognostic. The next COG FHWT study will implement and validate these findings.

Author List

Renfro LA, Vallance KL, Tfirn IC, Evageliou N, Benedetti DJ, Shamberger RC, Ehrlich PF, Cost NG, Aldrink JH, Schechter A, Treece A, Parsons LN, Walz AL, Sutton KS, Armstrong AE, Fernandez CV, Dome JS, Geller JI, Mullen EA, AREN03B2 Authorship Group

Author

Lauren Parsons MD Associate Professor in the Pathology and Laboratory Medicine department at Medical College of Wisconsin